Transport
HMH Hospitals Corporation
HMH Hospitals Corporation was paid $333.03M by Medicaid between Jan 2018 and Dec 2024, across 656 billing codes. Its largest line is 99284, emergency room visit (serious) — 10% of everything it billed.
33Billing provider infoHMH HOSPITALS CORPORATION
HACKENSACK, NJ 07601
HACKENSACK, NJ 07601
33aNPI1457456279assigned 09/14/2006
33bProvider typeAmbulance
28Total paid$333.03M
24GClaims3,535,028
24DCodes billed656
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulance providers in New Jersey
Rank by total paid#1 of 81
Median peer was paid$90K
This provider vs. median3,699×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 358,951 | $43.26M | |
| 2019 | 391,361 | $41.39M | |
| 2020 | 310,275 | $33.39M | |
| 2021 | 476,743 | $44.13M | |
| 2022 | 634,683 | $56.18M | |
| 2023 | 737,670 | $59.93M | |
| 2024incomplete | 625,345 | $54.74M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 84,594 | 77,988 | $33.71M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.4% | 107,058 | 99,499 | $31.24M |
| G0378 | Hospital observation service, per hour | 5.8% | 19,271 | 16,536 | $19.28M |
| J9271 | Injection, pembrolizumab, 1 mg | 5.1% | 1,681 | 1,185 | $17.05M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.7% | 31,445 | 29,425 | $12.28M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 3.5% | 30,602 | 17,185 | $11.66M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 3.2% | 1,184 | 1,101 | $10.67M |
| J9312 | Injection, rituximab, 10 mg | 2.1% | 1,113 | 603 | $7.06M |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.0% | 46,520 | 32,620 | $6.71M |
| J9306 | Injection, pertuzumab, 1 mg | 1.7% | 831 | 609 | $5.74M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 24,881 | 23,240 | $5.69M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.5% | 2,738 | 2,644 | $5.04M |
644 more codes
| J9299 | Injection, nivolumab, 1 mg | 1.5% | 773 | $4.99M |
| A0429 | Emergency ambulance ride, basic life support | 1.5% | 19,775 | $4.87M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 30,434 | $4.73M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.2% | 18,468 | $3.85M |
| J0897 | Injection, denosumab, 1 mg | 1.1% | 1,867 | $3.76M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 33,561 | $3.61M |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 1.1% | 2,015 | $3.50M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.0% | 7,010 | $3.49M |
| A0427 | Emergency ambulance ride, advanced life support | 1.0% | 10,854 | $3.42M |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 3,100 | $3.06M |
| 93458 | <1% | 933 | $2.90M | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 4,947 | $2.87M |
| 36430 | <1% | 6,572 | $2.83M | |
| J9310 | Injection, rituximab, 100 mg | <1% | 338 | $2.66M |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | <1% | 458 | $2.62M |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | <1% | 680 | $2.26M |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 1,955 | $2.26M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,964 | $2.16M |
| 96367 | <1% | 13,362 | $2.11M | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 46,358 | $1.88M |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 824 | $1.87M |
| 92587 | <1% | 9,330 | $1.86M | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 15,673 | $1.85M |
| 94060 | <1% | 3,365 | $1.72M | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 16,440 | $1.70M |
| 94010 | <1% | 4,890 | $1.67M | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 9,712 | $1.66M |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 293 | $1.63M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 31,803 | $1.62M |
| 96409 | <1% | 3,205 | $1.60M | |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | <1% | 715 | $1.55M |
| J0485 | Injection, belatacept, 1 mg | <1% | 1,345 | $1.53M |
| 96411 | <1% | 3,408 | $1.46M | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 4,358 | $1.45M |
| 80053 | Comprehensive metabolic panel | <1% | 127,284 | $1.35M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 79,896 | $1.34M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 501 | $1.33M |
| OP710 | <1% | 16,544 | $1.30M | |
| A0425 | Ground mileage, per statute mile | <1% | 34,108 | $1.28M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 931 | $1.26M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 53,490 | $1.26M |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 3,642 | $1.25M |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,387 | $1.15M |
| 71046 | Radiologic examination, chest; 2 views | <1% | 39,527 | $1.15M |
| OP278 | <1% | 1,615 | $1.13M | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 12,360 | $1.12M |
| 96401 | <1% | 4,017 | $1.09M | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 2,989 | $1.06M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 5,219 | $1.05M |
| 96402 | <1% | 2,668 | $974K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 7,345 | $971K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 19,930 | $969K |
| 44970 | <1% | 408 | $949K | |
| 92567 | <1% | 10,579 | $922K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 10,863 | $920K |
| Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | <1% | 356 | $895K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 20,367 | $891K |
| 95117 | <1% | 9,351 | $881K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 144,070 | $856K |
| 92557 | <1% | 3,607 | $842K | |
| 74183 | <1% | 1,475 | $813K | |
| 92652 | <1% | 1,109 | $785K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 2,217 | $784K |
| 93970 | <1% | 3,237 | $781K | |
| 95782 | <1% | 556 | $774K | |
| P9037 | Platelets, pheresis, leukocytes reduced, irradiated, each unit | <1% | 492 | $769K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,946 | $763K |
| A0434 | Specialty care transport (sct) | <1% | 1,895 | $745K |
| 92579 | <1% | 3,814 | $730K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 11,184 | $723K |
| 93976 | <1% | 2,503 | $723K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 2,105 | $690K |
| 77412 | <1% | 7,946 | $678K | |
| 92585 | <1% | 681 | $662K | |
| 94729 | <1% | 2,512 | $660K | |
| J9202 | Goserelin acetate implant, per 3.6 mg | <1% | 657 | $660K |
| OP250 | <1% | 248,938 | $628K | |
| 92582 | <1% | 2,929 | $627K | |
| 94727 | <1% | 2,497 | $626K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 21,160 | $623K |
| 77334 | <1% | 1,559 | $617K | |
| OP272 | <1% | 34,901 | $586K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,371 | $584K |
| OP370 | <1% | 8,127 | $564K | |
| 76830 | Ultrasound, transvaginal | <1% | 6,015 | $516K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 950 | $507K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 7,122 | $497K |
| 72197 | <1% | 1,032 | $487K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 4,553 | $484K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,335 | $480K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 374 | $475K |
| 93971 | <1% | 2,658 | $459K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 4,239 | $453K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 5,914 | $453K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 3,575 | $452K |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 1,863 | $452K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,900 | $443K |
| 76770 | <1% | 5,122 | $442K | |
| 96376 | <1% | 7,797 | $430K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,609 | $424K |
| 19083 | <1% | 238 | $419K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 5,012 | $418K |
| 71250 | <1% | 3,658 | $412K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,529 | $411K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 10,820 | $394K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 5,304 | $386K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 11,434 | $376K |
| 97161 | <1% | 8,354 | $344K | |
| 0002A | <1% | 10,426 | $338K | |
| J9395 | Injection, fulvestrant, 25 mg | <1% | 490 | $325K |
| 76801 | <1% | 2,881 | $309K | |
| 77066 | Tomosynthesis, mammo | <1% | 2,872 | $308K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,116 | $304K |
| 0001A | <1% | 10,575 | $303K | |
| 59025 | Fetal non-stress test | <1% | 2,571 | $294K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 13,868 | $293K |
| 95819 | <1% | 585 | $288K | |
| 71045 | Radiologic examination, chest; single view | <1% | 12,319 | $288K |
| 93017 | <1% | 1,688 | $287K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,332 | $284K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 2,598 | $282K |
| C1776 | Joint device (implantable) | <1% | 123 | $282K |
| 99245 | <1% | 2,342 | $279K | |
| 88185 | <1% | 2,308 | $277K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 3,134 | $274K |
| 92555 | <1% | 2,572 | $269K | |
| 76641 | <1% | 2,980 | $266K | |
| 96416 | <1% | 2,530 | $266K | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 320 | $265K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 25,815 | $263K |
| 96415 | <1% | 8,982 | $249K | |
| 77065 | Tomosynthesis, mammo | <1% | 2,970 | $237K |
| 70491 | <1% | 1,511 | $231K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 498 | $228K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 150 | $221K |
| J9358 | Injection, fam-trastuzumab deruxtecan-nxki, 1 mg | <1% | 32 | $212K |
| 70486 | <1% | 1,545 | $210K | |
| OP270 | <1% | 63,778 | $210K | |
| 84484 | <1% | 30,780 | $206K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 10,219 | $206K |
| 76642 | <1% | 3,577 | $203K | |
| 96368 | <1% | 3,187 | $202K | |
| 95800 | <1% | 491 | $199K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 8,924 | $196K |
| 47562 | <1% | 100 | $189K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,427 | $186K |
| 36591 | <1% | 2,209 | $185K | |
| 73564 | <1% | 5,272 | $184K | |
| 36561 | <1% | 98 | $178K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 5,050 | $176K |
| 86900 | <1% | 30,811 | $173K | |
| 77080 | <1% | 2,452 | $171K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 996 | $168K |
| 77336 | <1% | 2,109 | $167K | |
| 76813 | <1% | 1,316 | $166K | |
| 70496 | <1% | 1,259 | $164K | |
| 86850 | <1% | 27,268 | $164K | |
| 93356 | <1% | 938 | $152K | |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 3,177 | $152K |
| 83735 | <1% | 41,832 | $149K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 17,479 | $147K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 21,125 | $147K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 20,392 | $145K |
| 76536 | <1% | 2,273 | $141K | |
| 73030 | <1% | 4,405 | $140K | |
| 70498 | <1% | 1,097 | $138K | |
| C9463 | Injection, aprepitant, 1 mg | <1% | 323 | $137K |
| 96417 | <1% | 7,397 | $137K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 391 | $134K |
| 81001 | <1% | 41,472 | $133K | |
| 73130 | <1% | 4,750 | $131K | |
| 95714 | <1% | 513 | $131K | |
| 72141 | <1% | 532 | $130K | |
| 86803 | <1% | 15,449 | $126K | |
| J9070 | Cyclophosphamide, 100 mg | <1% | 477 | $125K |
| C9062 | Injection, daratumumab 10 mg and hyaluronidase-fihj | <1% | 20 | $124K |
| 92526 | <1% | 2,371 | $123K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,217 | $119K |
| 73630 | <1% | 4,395 | $118K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 41,200 | $117K |
| OP258 | <1% | 130,447 | $117K | |
| 86901 | <1% | 31,625 | $115K | |
| 93880 | <1% | 551 | $114K | |
| 87507 | <1% | 1,537 | $112K | |
| C1769 | Guide wire | <1% | 4,226 | $112K |
| 73562 | <1% | 3,005 | $111K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 5,139 | $111K |
| 81268 | <1% | 1,008 | $110K | |
| 36592 | <1% | 945 | $110K | |
| 73610 | <1% | 4,535 | $109K | |
| 76870 | <1% | 1,840 | $109K | |
| 97162 | <1% | 1,960 | $108K | |
| 84702 | <1% | 12,397 | $106K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 20,972 | $104K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 4,275 | $102K |
| 74018 | <1% | 4,326 | $102K | |
| 54161 | <1% | 40 | $100K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 9,831 | $100K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 659 | $99K |
| 83605 | <1% | 15,219 | $99K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 97,017 | $98K |
| 97010 | <1% | 23,893 | $96K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 13,602 | $94K |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 3,158 | $91K |
| J3490 | Unclassified drugs | <1% | 9,181 | $90K |
| 88341 | <1% | 2,048 | $89K | |
| 77290 | <1% | 381 | $89K | |
| 74174 | <1% | 494 | $87K | |
| 83690 | <1% | 21,950 | $87K | |
| 93798 | <1% | 874 | $87K | |
| J2704 | Injection, propofol, 10 mg | <1% | 24,007 | $86K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 8,891 | $86K |
| 72110 | <1% | 2,073 | $83K | |
| J9047 | Injection, carfilzomib, 1 mg | <1% | 74 | $83K |
| 83880 | <1% | 8,024 | $82K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 30,614 | $79K |
| 72082 | <1% | 1,433 | $79K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 10,764 | $78K |
| 87040 | <1% | 5,109 | $78K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 906 | $77K |
| 73110 | <1% | 2,688 | $76K | |
| 85610 | <1% | 19,739 | $75K | |
| 74019 | <1% | 2,493 | $74K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 2,561 | $74K |
| 12011 | <1% | 1,692 | $71K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 1,384 | $69K |
| 96040 | <1% | 723 | $67K | |
| 88342 | <1% | 4,914 | $67K | |
| 95700 | <1% | 412 | $67K | |
| 97116 | <1% | 4,805 | $67K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,171 | $66K |
| J3590 | Unclassified biologics | <1% | 280 | $66K |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 2,421 | $65K |
| 12001 | <1% | 1,537 | $65K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 3,590 | $64K |
| 73590 | <1% | 2,367 | $63K | |
| 87799 | <1% | 5,052 | $63K | |
| 85730 | <1% | 16,847 | $62K | |
| 97802 | <1% | 251 | $61K | |
| 86923 | <1% | 4,210 | $61K | |
| 73080 | <1% | 1,974 | $60K | |
| 82962 | <1% | 28,256 | $60K | |
| 97113 | <1% | 1,732 | $59K | |
| 81003 | <1% | 23,671 | $59K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,173 | $59K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 10,286 | $58K |
| 88184 | <1% | 2,494 | $57K | |
| 78816 | <1% | 54 | $54K | |
| 87486 | <1% | 3,563 | $52K | |
| 72131 | <1% | 796 | $52K | |
| 87581 | <1% | 3,564 | $52K | |
| 87070 | <1% | 8,490 | $51K | |
| 73502 | <1% | 2,199 | $51K | |
| 96523 | <1% | 358 | $50K | |
| 84100 | <1% | 25,005 | $50K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 9,332 | $49K |
| C1874 | Stent, coated/covered, with delivery system | <1% | 96 | $49K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 804 | $48K |
| 85027 | <1% | 12,202 | $48K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12,201 | $48K |
| 92604 | <1% | 141 | $48K | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 30 | $47K |
| 77072 | <1% | 1,606 | $47K | |
| 64483 | <1% | 25 | $46K | |
| 72158 | <1% | 134 | $46K | |
| 78306 | <1% | 486 | $45K | |
| 90715 | <1% | 2,841 | $45K | |
| 96450 | <1% | 91 | $44K | |
| 93296 | <1% | 1,787 | $43K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 120 | $43K |
| 97597 | <1% | 310 | $42K | |
| 88304 | <1% | 2,887 | $42K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 37 | $41K |
| 80061 | Lipid panel | <1% | 6,739 | $41K |
| 99354 | <1% | 361 | $41K | |
| 10060 | <1% | 499 | $41K | |
| 74178 | <1% | 166 | $40K | |
| 87186 | <1% | 5,986 | $40K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 504 | $39K |
| 77300 | <1% | 195 | $38K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 3,528 | $38K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 12,607 | $36K |
| 73090 | <1% | 1,443 | $36K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 1,368 | $36K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,249 | $36K |
| 86140 | <1% | 13,017 | $36K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 503 | $35K |
| 88307 | <1% | 1,020 | $35K | |
| 82805 | <1% | 2,053 | $35K | |
| 87340 | <1% | 9,363 | $34K | |
| 82077 | <1% | 4,671 | $32K | |
| 97165 | <1% | 956 | $32K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 2,895 | $32K |
| 73560 | <1% | 1,338 | $32K | |
| 92550 | <1% | 278 | $31K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,067 | $31K |
| 90677 | <1% | 131 | $31K | |
| 73552 | <1% | 1,300 | $31K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 10,798 | $31K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,966 | $31K |
| 87077 | <1% | 4,636 | $31K | |
| 85045 | <1% | 8,726 | $31K | |
| 87634 | <1% | 1,769 | $30K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,732 | $30K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 1,548 | $30K |
| 76821 | <1% | 431 | $30K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 9,084 | $29K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 27,547 | $29K |
| 99417 | Prolong home eval add 15m | <1% | 1,756 | $29K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 7,865 | $29K |
| 81025 | <1% | 6,706 | $28K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,204 | $26K |
| 76820 | <1% | 501 | $25K | |
| 87497 | <1% | 2,646 | $25K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 4,780 | $25K |
| J9370 | Vincristine sulfate, 1 mg | <1% | 1,911 | $25K |
| 80197 | <1% | 4,406 | $24K | |
| 92610 | <1% | 103 | $23K | |
| 80143 | <1% | 2,798 | $21K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 4,588 | $21K |
| 83615 | <1% | 9,225 | $21K | |
| 73523 | <1% | 524 | $21K | |
| 80179 | <1% | 2,653 | $21K | |
| OP682 | <1% | 40 | $20K | |
| 72156 | <1% | 48 | $20K | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 871 | $20K |
| 29125 | <1% | 699 | $20K | |
| 92523 | <1% | 299 | $20K | |
| 70544 | <1% | 85 | $19K | |
| 72157 | <1% | 40 | $19K | |
| 97803 | <1% | 185 | $18K | |
| 82728 | <1% | 3,661 | $18K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 4,040 | $18K |
| 84550 | <1% | 8,919 | $17K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 5,173 | $17K |
| 72100 | <1% | 600 | $17K | |
| 90670 | <1% | 120 | $17K | |
| 73700 | <1% | 158 | $16K | |
| 85652 | <1% | 8,052 | $16K | |
| 82550 | <1% | 3,996 | $16K | |
| 95957 | <1% | 218 | $15K | |
| 36600 | <1% | 800 | $15K | |
| OP229 | <1% | 291 | $15K | |
| 73521 | <1% | 416 | $14K | |
| 77295 | <1% | 24 | $14K | |
| 81267 | <1% | 856 | $14K | |
| J9206 | Injection, irinotecan, 20 mg | <1% | 514 | $14K |
| 73060 | <1% | 633 | $14K | |
| 0003A | <1% | 438 | $14K | |
| 93351 | <1% | 66 | $14K | |
| 0031A | <1% | 423 | $14K | |
| 85379 | <1% | 3,752 | $13K | |
| 76000 | <1% | 279 | $13K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 9,008 | $13K |
| 77280 | <1% | 92 | $13K | |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 91 | $13K |
| 76604 | <1% | 360 | $12K | |
| 82248 | <1% | 2,295 | $12K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 119 | $12K |
| 70543 | <1% | 31 | $12K | |
| P9073 | Platelets, pheresis, pathogen-reduced, each unit | <1% | 163 | $11K |
| 76882 | <1% | 357 | $11K | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 3,946 | $11K |
| 71101 | <1% | 307 | $11K | |
| 97166 | <1% | 187 | $10K | |
| 84439 | <1% | 4,327 | $10K | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 410 | $10K |
| 86704 | <1% | 2,270 | $10K | |
| 77417 | <1% | 227 | $10K | |
| 82784 | <1% | 2,313 | $9K | |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | <1% | 505 | $9K |
| 80076 | <1% | 1,966 | $9K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,373 | $9K |
| 82607 | <1% | 1,999 | $9K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 73 | $9K |
| 73100 | <1% | 314 | $9K | |
| 81002 | <1% | 7,232 | $9K | |
| 87205 | <1% | 2,964 | $9K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 2,558 | $8K |
| J9000 | Injection, doxorubicin hydrochloride, 10 mg | <1% | 405 | $8K |
| 88313 | <1% | 954 | $8K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 1,439 | $8K |
| 86360 | <1% | 1,245 | $8K | |
| 84145 | <1% | 791 | $8K | |
| 0071A | <1% | 210 | $8K | |
| 86780 | <1% | 2,263 | $8K | |
| 86706 | <1% | 2,221 | $8K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 339 | $7K |
| A4648 | Tissue marker, implantable, any type, each | <1% | 1,011 | $7K |
| 87522 | Neg quan hep c or qual rna | <1% | 1,401 | $7K |
| G0008 | Administration of influenza virus vaccine | <1% | 734 | $7K |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 186 | $7K |
| 92540 | <1% | 14 | $7K | |
| 0072A | <1% | 195 | $7K | |
| 72040 | <1% | 245 | $7K | |
| 86480 | <1% | 1,253 | $7K | |
| 86922 | <1% | 477 | $7K | |
| 86921 | <1% | 492 | $7K | |
| J9075 | Injection, cyclophosphamide, not otherwise specified, 5 mg | <1% | 20 | $7K |
| 84480 | <1% | 866 | $7K | |
| 90686 | <1% | 625 | $7K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,868 | $6K |
| 29581 | <1% | 51 | $6K | |
| 72146 | <1% | 25 | $6K | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 4,516 | $6K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,448 | $6K |
| 76981 | <1% | 112 | $6K | |
| 83550 | <1% | 2,415 | $6K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,745 | $6K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 362 | $6K |
| 86359 | <1% | 1,265 | $6K | |
| 83540 | <1% | 2,673 | $6K | |
| 0004A | <1% | 171 | $6K | |
| 82948 | <1% | 3,196 | $6K | |
| 12002 | <1% | 134 | $6K | |
| 90837 | Psychotherapy session, about an hour | <1% | 90 | $5K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 410 | $5K |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 96 | $5K |
| 82150 | <1% | 1,368 | $5K | |
| 88360 | <1% | 350 | $5K | |
| 84156 | <1% | 2,007 | $5K | |
| 72170 | <1% | 358 | $5K | |
| 86902 | <1% | 466 | $5K | |
| 95951 | <1% | 20 | $5K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,315 | $5K |
| 83970 | <1% | 569 | $5K | |
| 15853 | <1% | 77 | $5K | |
| 84153 | <1% | 671 | $5K | |
| 0064A | <1% | 155 | $5K | |
| 82570 | <1% | 2,900 | $5K | |
| 86665 | <1% | 1,183 | $5K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 676 | $5K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 4,901 | $5K |
| C1781 | Mesh (implantable) | <1% | 12 | $4K |
| 64642 | <1% | 14 | $4K | |
| 93298 | <1% | 231 | $4K | |
| 82746 | <1% | 900 | $4K | |
| 86357 | <1% | 1,053 | $4K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 305 | $4K |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 1,501 | $4K |
| 87536 | <1% | 154 | $4K | |
| 86870 | <1% | 116 | $4K | |
| 86769 | <1% | 253 | $4K | |
| 87088 | <1% | 2,905 | $4K | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 1,134 | $4K |
| 36593 | <1% | 19 | $4K | |
| 82977 | <1% | 1,981 | $4K | |
| 80074 | <1% | 229 | $4K | |
| 97168 | <1% | 64 | $4K | |
| 72052 | <1% | 74 | $3K | |
| 73000 | <1% | 119 | $3K | |
| 86355 | <1% | 1,062 | $3K | |
| 85384 | <1% | 879 | $3K | |
| 76942 | <1% | 77 | $3K | |
| 84436 | <1% | 690 | $3K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 6,709 | $3K |
| 73070 | <1% | 126 | $3K | |
| 89051 | <1% | 1,375 | $3K | |
| 75574 | <1% | 15 | $3K | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 189 | $3K |
| 93293 | <1% | 182 | $3K | |
| 97016 | <1% | 1,984 | $3K | |
| 87075 | <1% | 740 | $3K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 146 | $3K |
| 73120 | <1% | 89 | $3K | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 334 | $3K |
| 86787 | <1% | 1,021 | $3K | |
| 87400 | <1% | 210 | $3K | |
| 88311 | <1% | 1,040 | $3K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 432 | $3K |
| 70487 | <1% | 15 | $2K | |
| 80047 | <1% | 667 | $2K | |
| 64643 | <1% | 15 | $2K | |
| 82010 | <1% | 708 | $2K | |
| 0053A | <1% | 69 | $2K | |
| 83655 | <1% | 641 | $2K | |
| 29105 | <1% | 39 | $2K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 81 | $2K |
| 77332 | <1% | 37 | $2K | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 115 | $2K |
| 72072 | <1% | 82 | $2K | |
| 86644 | <1% | 1,044 | $2K | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 733 | $2K |
| 84703 | <1% | 2,082 | $2K | |
| 70480 | <1% | 12 | $2K | |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 190 | $2K |
| 73620 | <1% | 78 | $2K | |
| 88112 | <1% | 396 | $2K | |
| 83520 | <1% | 391 | $2K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,427 | $2K |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 611 | $2K |
| 86038 | <1% | 496 | $2K | |
| 83020 | <1% | 853 | $2K | |
| 87449 | <1% | 567 | $2K | |
| Q9961 | High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml | <1% | 43 | $2K |
| 88108 | <1% | 345 | $2K | |
| OP637 | <1% | 9,038 | $2K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 2,424 | $2K |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 2,436 | $1K |
| 82247 | <1% | 340 | $1K | |
| 86160 | <1% | 171 | $1K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 190 | $1K |
| 87641 | <1% | 161 | $1K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 267 | $1K |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 296 | $1K |
| 87305 | <1% | 467 | $1K | |
| 87420 | <1% | 110 | $1K | |
| 90656 | <1% | 86 | $1K | |
| 86645 | <1% | 871 | $1K | |
| 87081 | <1% | 380 | $1K | |
| 85014 | <1% | 691 | $1K | |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 139 | $1K |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 56 | $1K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 287 | $1K |
| 94644 | <1% | 43 | $1K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 181 | $1K |
| 84132 | <1% | 962 | $1K | |
| 0054A | <1% | 31 | $940.74 | |
| 82533 | <1% | 377 | $927.66 | |
| 94760 | <1% | 226 | $906.47 | |
| 0052A | <1% | 26 | $904.34 | |
| M0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring | <1% | 14 | $903.00 |
| 90723 | <1% | 15 | $900.65 | |
| 84157 | <1% | 753 | $899.55 | |
| 73600 | <1% | 31 | $825.65 | |
| 74241 | <1% | 12 | $811.80 | |
| 76776 | <1% | 31 | $799.53 | |
| 92593 | <1% | 12 | $794.64 | |
| C1788 | Port, indwelling (implantable) | <1% | 42 | $786.94 |
| 85660 | <1% | 1,034 | $771.47 | |
| 76010 | <1% | 44 | $768.62 | |
| 88300 | <1% | 248 | $767.20 | |
| 82945 | <1% | 747 | $738.16 | |
| 84403 | <1% | 124 | $727.06 | |
| 84146 | <1% | 144 | $679.99 | |
| 77001 | <1% | 15 | $638.30 | |
| 90648 | <1% | 28 | $635.34 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 687 | $627.10 |
| 87496 | <1% | 15 | $625.55 | |
| 93280 | <1% | 26 | $607.79 | |
| 74240 | <1% | 13 | $569.44 | |
| 86788 | <1% | 478 | $566.11 | |
| 87147 | <1% | 229 | $555.71 | |
| 83002 | <1% | 133 | $542.73 | |
| 70160 | <1% | 13 | $539.58 | |
| 86703 | <1% | 41 | $532.56 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 187 | $528.22 |
| 76937 | <1% | 12 | $521.02 | |
| 0051A | <1% | 15 | $520.00 | |
| J9260 | Injection, methotrexate sodium, 50 mg | <1% | 206 | $518.21 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 1,326 | $487.90 |
| 83001 | <1% | 131 | $470.91 | |
| 86789 | <1% | 477 | $469.27 | |
| 87640 | <1% | 162 | $467.36 | |
| 29130 | <1% | 28 | $461.08 | |
| 29515 | <1% | 14 | $450.87 | |
| 86664 | <1% | 362 | $437.79 | |
| 86308 | <1% | 203 | $434.30 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 519 | $431.79 |
| J0456 | Injection, azithromycin, 500 mg | <1% | 219 | $420.78 |
| 29505 | <1% | 13 | $420.34 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 86 | $418.41 |
| 88312 | <1% | 31 | $417.46 | |
| 82043 | <1% | 522 | $403.81 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 521 | $402.21 |
| 86364 | <1% | 305 | $393.27 | |
| 82610 | <1% | 305 | $391.43 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 61 | $387.46 |
| 0034A | <1% | 12 | $357.22 | |
| 90674 | <1% | 67 | $356.36 | |
| 86682 | <1% | 348 | $353.07 | |
| 0012A | <1% | 24 | $347.23 | |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | <1% | 144 | $335.44 |
| 87324 | <1% | 218 | $318.07 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 222 | $317.00 |
| 87154 | <1% | 13 | $313.45 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 136 | $310.09 |
| 86762 | <1% | 102 | $298.89 | |
| J0290 | Injection, ampicillin sodium, 500 mg | <1% | 102 | $295.20 |
| 82105 | <1% | 136 | $286.14 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 666 | $273.65 |
| 87517 | <1% | 30 | $270.17 | |
| 70250 | <1% | 18 | $246.84 | |
| 87206 | <1% | 150 | $243.72 | |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 58 | $231.19 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 160 | $225.50 |
| 80177 | <1% | 40 | $223.53 | |
| 86376 | <1% | 90 | $221.68 | |
| 88302 | <1% | 28 | $219.64 | |
| 80164 | <1% | 116 | $219.26 | |
| 86592 | <1% | 120 | $212.35 | |
| 85347 | <1% | 53 | $197.26 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 43 | $183.50 |
| 86833 | <1% | 12 | $163.65 | |
| 85007 | <1% | 79 | $163.46 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 62 | $160.28 |
| 82785 | <1% | 16 | $149.67 | |
| 82140 | <1% | 65 | $145.08 | |
| 86832 | <1% | 12 | $136.80 | |
| 82670 | <1% | 17 | $134.14 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 209 | $133.91 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 86 | $129.81 |
| 87106 | <1% | 15 | $116.83 | |
| 70360 | <1% | 15 | $114.58 | |
| 88173 | <1% | 26 | $108.95 | |
| 84681 | <1% | 18 | $105.63 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 264 | $99.43 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 117 | $99.11 |
| OP940 | <1% | 165 | $85.71 | |
| 84305 | <1% | 50 | $85.04 | |
| 82330 | <1% | 38 | $73.69 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 77 | $69.35 |
| 83519 | <1% | 18 | $66.80 | |
| 86800 | <1% | 60 | $65.96 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 44 | $65.76 |
| 82465 | <1% | 25 | $61.66 | |
| 86618 | <1% | 13 | $58.35 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 20 | $51.97 |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | <1% | 536 | $50.28 |
| 82947 | <1% | 15 | $45.15 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 14 | $34.64 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 14 | $32.11 |
| J1643 | Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units | <1% | 77 | $31.59 |
| 84295 | <1% | 90 | $30.87 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 65 | $24.67 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 12 | $23.09 |
| 91300 | <1% | 19,356 | $21.01 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 69 | $19.44 |
| 84165 | <1% | 13 | $17.18 | |
| 86765 | <1% | 48 | $10.00 | |
| 36416 | <1% | 31 | $9.44 | |
| 83516 | <1% | 36 | $9.00 | |
| 82040 | <1% | 16 | $8.69 | |
| Q0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg | <1% | 14 | $6.00 |
| 91306 | 0% | 164 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 16 | $0.00 |
| 91307 | 0% | 361 | $0.00 | |
| 91301 | 0% | 29 | $0.00 | |
| 91305 | 0% | 154 | $0.00 | |
| C9600 | Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch | 0% | 14 | $0.00 |
| 91303 | 0% | 360 | $0.00 | |
| 96111 | 0% | 12 | $0.00 | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 20 | $0.00 |
| 99152 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSAWCZUK, IHOR (PRESIDENT - HUMC)
| Provider | Location | Paid |
|---|---|---|
| HMH Hospitals Corporation | North Bergen, NJ | $79.26M |
| HMH Hospitals Corporation | Perth Amboy, NJ | $65.37M |
| HMH Hospitals Corporation | Brick, NJ | $49.91M |
| HMH Hospitals Corporation | Holmdel, NJ | $29.33M |
| HMH Hospitals Corporation | Red Bank, NJ | $26.39M |
| HMH Hospitals Corporation | Old Bridge, NJ | $18.66M |
| HMH Hospitals Corporation | Brick, NJ | $575K |
| Hackensack Specialty Care Associates, PC | Hackensack, NJ | $141K |
| Humc Medical Observation | Hackensack, NJ | $14K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.